| Literature DB >> 34993006 |
Damien Oudin Doglioni1,2, Anne-Laure Pham-Hung D'Alexandry D'Orengiani3, Frédéric Galactéros3,4, Marie-Claire Gay2.
Abstract
OBJECTIVE: Sickle cell disease (SCD) is the most frequent monogenic disease worldwide. Psychological and behavioural factors are often reported as playing a significant role in predicting SCD health outcomes. When focusing on adaptation to a specific health condition and its treatment, the Common Sense Model of Health and Illness (CSM) has proven to be of heuristic value. In other health conditions, illness outcomes are directly influenced by illness perception. Therefore, the aim of this study is to explore the psychometric proprieties of the Revised Illness Perception Questionnaire (IPQ-R).Entities:
Keywords: Common Sens Model; Illness Perception Questionnaire-Revised; Sickle cell disease; confirmatory factor analysis; psychometric
Year: 2021 PMID: 34993006 PMCID: PMC8725854 DOI: 10.1080/21642850.2021.2016411
Source DB: PubMed Journal: Health Psychol Behav Med ISSN: 2164-2850
Interpretation of IPQ-R dimension scores (from Nicholls et al., 2013).
| Dimensions | Interpretation |
| Timeline acute/chronic | Illness will last a long time |
| Timeline cyclical | Condition is cyclical in nature |
| Consequences | Condition has a major impact on life |
| Personal control | Good perceived personal control over symptoms |
| Treatment control/Cure | Treatment could control symptoms |
| Illness coherence | Understanding of condition |
| Emotional representation | Condition affects patients emotionally |
Comparison of the goodness of fit indices between the nine studies that explored the psychometric properties of the IPQ-R.
| > 0.90 | > 0.90 | <0.08 | <0.07 | <5 | ||||
| Surgenor, L. J., Snell, D. L., Siegert, R. J., Kelly, S., Flint, R., & Coulter, G. (2019). | 310 | ? | ? | ? | ? | ? | ? | No data provided |
| Ashley, L., Smith, A. B., Keding, A., Jones, H., Velikova, G., & Wright, | 531 | 0.80 | 0.086 | 0.042 | 1.766 | |||
| Nicholls, E. E., Hill, S., & Foster, N. E. (2013). | 330 | 0.86 | 0.064 | 2.338 | ||||
| 1621 | 0.86 | 0.068 | 8.495 | |||||
| 1319 | 0.90 | 0.059 | 5.635 | |||||
| Brzoska, | 302 | 0.785 | 0.765 | 0.109 | 0.075 | 3.722 | 18177.43 | |
| Abubakari, A.-R., Jones, M. C., Lauder, W., Kirk, A., Devendra, D., & Anderson, J. (2012). | 221 | 0.83 | 0.81 | 0.06 | 1.707 | |||
| Dempster, M., & McCorry, N. K. (2012). | 587 | 0.94 | 0.070 | 0.068 | 3.707 | |||
| Cabassa, L. J., Lagomasino, I. T., Dwight-Johnson, M., Hansen, M. C., & Xie, B. (2008). | 339 | 0.793 | 0.768 | 0.069 | 2.598 | |||
| Wittkowski, A., Richards, H. L., Williams, J., & Main, C. J. (2008). | 284 | 0.798 | 0.085 | 3.061 | ||||
| Hagger, M. S., & Orbell, S. (2005). | 660 | 0.911 | 0.904 | 0.042 | ||||
| > 0.90 | > 0.90 | <0.08 | <0.07 | <5 | ||||
| Surgenor, L. J., Snell, D. L., Siegert, R. J., Kelly, S., Flint, R., & Coulter, G. (2019). | 310 | ? | ? | ? | ? | ? | 19, 23 | |
| Ashley, L., Smith, A. B., Keding, A., Jones, H., Velikova, G., & Wright, | 531 | 0.904 | 0.058 | 0.057 | 2.722 | 12, 18, 24, 32 | ||
| Nicholls, E. E., Hill, S., & Foster, N. E. (2013). | 330 | 0.89 | 0.064 | 2.344 | 15, 17, 19, 23, 37, 38 | |||
| 1621 | 0.90 | 0.065 | 7.801 | |||||
| 1319 | 0.92 | 0.058 | 5.452 | |||||
| Brzoska, | 302 | 0.877 | 0.864 | 0.083 | 0.059 | 2.924 | 15404.43 | 17, 19, 20, 31 |
| Abubakari, A.-R., Jones, M. C., Lauder, W., Kirk, A., Devendra, D., & Anderson, J. (2012). | 221 | 0.86 | 0.85 | 0.06 | 1.669 | 19, 20, 24, | ||
| Dempster, M., & McCorry, N. K. (2012). | 587 | 0.94 | 0.070 | 0.068 | 3.707 | |||
| Cabassa, L. J., Lagomasino, I. T., Dwight-Johnson, M., Hansen, M. C., & Xie, B. (2008). | 339 | 0.827 | 0.802 | 0.069 | 2.620 | 15, 17, 19 | ||
| Wittkowski, A., Richards, H. L., Williams, J., & Main, C. J. (2008). | 284 | 0.798 | 0.085 | 3.061 | ||||
| Hagger, M. S., & Orbell, S. (2005). | 660 | 0.926 | 0.920 | 0.040 | 9, 10 | |||
| > 0.90 | > 0.90 | <0.08 | <0.07 | <5 | ||||
| Surgenor, L. J., Snell, D. L., Siegert, R. J., Kelly, S., Flint, R., & Coulter, G. (2019). | 310 | ? | ? | ? | ? | ? | ? | 1&4 |
| Ashley, L., Smith, A. B., Keding, A., Jones, H., Velikova, G., & Wright, | 531 | 0.859 | 0.079 | 0.037 | 1.526 | 1&4 | ||
| Nicholls, E. E., Hill, S., & Foster, N. E. (2013). | 330 | 0.89 | 0.064 | 2.344 | ||||
| 1621 | 0.90 | 0.065 | 7.801 | |||||
| 1319 | 0.92 | 0.058 | 5.452 | |||||
| Brzoska, | 302 | 0.911 | 0.901 | 0.079 | 0.050 | 2.502 | 15189.58 | 33&34 |
| Abubakari, A.-R., Jones, M. C., Lauder, W., Kirk, A., Devendra, D., & Anderson, J. (2012). | 221 | 0.89 | 0.88 | 0.05 | 1.522 | 1&4 | ||
| Dempster, M., & McCorry, N. K. (2012). | 587 | 0.95 | 0.061 | 0.064 | 3.430 | 1&4 | ||
| Cabassa, L. J., Lagomasino, I. T., Dwight-Johnson, M., Hansen, M. C., & Xie, B. (2008). | 339 | 0.908 | 0.900 | 0.051 | 1.885 | 7 errors covariances non-specified | ||
| Wittkowski, A., Richards, H. L., Williams, J., & Main, C. J. (2008). | 284 | 0.798 | 0.085 | 3.061 | ||||
| Hagger, M. S., & Orbell, S. (2005). | 660 | 0.926 | 0.920 | 0.040 | ||||
| > 0.90 | > 0.90 | <0.08 | <0.07 | <5 | ||||
| Surgenor, L. J., Snell, D. L., Siegert, R. J., Kelly, S., Flint, R., & Coulter, G. (2019). | 310 | ? | ? | ? | ? | ? | ? | |
| Ashley, L., Smith, A. B., Keding, A., Jones, H., Velikova, G., & Wright, | 531 | 0.859 | 0.079 | 0.037 | 1.526 | |||
| Nicholls, E. E., Hill, S., & Foster, N. E. (2013). | 330 | 0.89 | 0.064 | 2.344 | ||||
| 1621 | 0.90 | 0.065 | 7.801 | |||||
| 1319 | 0.92 | 0.058 | 5.452 | |||||
| Brzoska, | 302 | 0.929 | 0.921 | 0.067 | 0.045 | 2.282 | 15079.40 | 6 -> chronology |
| Abubakari, A.-R., Jones, M. C., Lauder, W., Kirk, A., Devendra, D., & Anderson, J. (2012). | 221 | 0.91 | 0.90 | 0.05 | 1.435 | |||
| Dempster, M., & McCorry, N. K. (2012). | 587 | 0.95 | 0.060 | 0.061 | 3.182 | 18 – >Treatment control | ||
| Cabassa, L. J., Lagomasino, I. T., Dwight-Johnson, M., Hansen, M. C., & Xie, B. (2008). | 339 | 0.908 | 0.900 | 0.051 | 1.885 | |||
| Wittkowski, A., Richards, H. L., Williams, J., & Main, C. J. (2008). | 284 | 0.798 | 0.085 | 3.061 | ||||
| Hagger, M. S., & Orbell, S. (2005). | 660 | 0.926 | 0.920 | 0.040 | ||||
The Revised Illness Perception Questionnaire (IPQ-R) seven core-factor items and modified Causal attribution scale.
| IPQ-R dimension | Item | English version | French translation | |
|---|---|---|---|---|
| Timeline acute/chronic | 1 | R | My sickle cell disease will last a short time | Ma drépanocytose ne va pas durer longtemps |
| 2 | My sickle cell disease is likely to be permanent rather than temporary | Ma drépanocytose est susceptible d’être permanente plutôt que temporaire | ||
| 3 | My sickle cell disease will last for a long time | Ma drépanocytose va durer longtemps | ||
| 4 | R | My sickle cell disease will pass quickly | Ma drépanocytose va rapidement passer | |
| 5 | I expect to have sickle cell disease for the rest of my life | Je pense que j’aurais la drépanocytose pour le restant de ma vie | ||
| 18 | R | My sickle cell disease will improve in time | Ma drépanocytose va s’améliorer avec le temps | |
| Consequences | 6 | My sickle cell disease is a serious condition | Ma drépanocytose est grave | |
| 7 | My sickle cell disease has major consequences in my life | Ma drépanocytose a des conséquences importantes sur ma vie | ||
| 8 | R | My sickle cell disease does not have much effect on my life | Ma drépanocytose n’a pas beaucoup d’effet sur ma vie | |
| 9 | My sickle cell disease strongly affects the way others see me | Ma drépanocytose affecte beaucoup la façon dont les autres me voient | ||
| 10 | My sickle cell disease has serious financial consequences | Ma drépanocytose a des conséquences financières graves | ||
| 11 | My sickle cell disease causes difficulties for those who are close to me | Ma drépanocytose cause des difficultés à mes proches | ||
| Personal control | 12 | There is a lot which I can do to control my symptoms | Il y a beaucoup de choses que je peux faire pour contrôler mes symptômes | |
| 13 | What I do can determine whether my sickle cell disease gets better or worse | Ce que je fais peut déterminer l’amélioration ou l’aggravation de ma drépanocytose | ||
| 14 | The course of my sickle cell disease depends on me | Le déroulement de ma drépanocytose dépend de moi | ||
| 15 | R | Nothing I do will affect my sickle cell disease | Rien de ce que je fais n’affectera ma drépanocytose | |
| 16 | I have the power to influence my sickle cell disease | J’ai le pouvoir d’influencer ma drépanocytose | ||
| 17 | R | My actions will have no effect on the outcome of my sickle cell disease | Mes actions n’auront aucun effet sur l’évolution de ma drépanocytose | |
| Treatment control | 19 | R | There is very little that can be done to improve my sickle cell disease | Il y a peu de choses à faire pour améliorer ma drépanocytose |
| 20 | My treatment will be effective in curing my sickle cell disease | Mon traitement sera efficace pour guérir ma drépanocytose | ||
| 21 | The negative effects of my sickle cell disease can be prevented (avoided) by my treatment | Les effets négatifs de ma drépanocytose peuvent être évités par mon traitement | ||
| 22 | My treatment can control my sickle cell disease | Mon traitement peut contrôler ma drépanocytose | ||
| 23 | R | There is nothing which can help my sickle cell disease | Rien ne peut aider mon état | |
| Illness coherence | 24 | R | The symptoms of my conditions are puzzling to me | Les symptômes de mon état me laissent perplexe |
| 25 | R | My sickle cell disease is a mystery to me | La drépanocytose est un mystère pour moi | |
| 26 | R | I don’t understand my sickle cell disease | Je ne comprends pas la drépanocytose | |
| 27 | R | My sickle cell disease doesn’t make any sense to me | La drépanocytose n’a aucun sens pour moi | |
| 28 | I have a clear picture or understanding of my condition | J’ai une image nette ou une compréhension de mon état | ||
| Timeline cyclical | 29 | The symptoms of my sickle cell disease change a great deal from day to day | Les symptômes de ma drépanocytose changent beaucoup d’un jour à l’autre | |
| 30 | My symptoms come and go in cycles | Mes symptômes vont et viennent par cycles | ||
| 31 | My sickle cell disease is very unpredictable | Ma drépanocytose est très imprévisible | ||
| 32 | I go through cycles in which my illness gets better and worse | Je passe par des cycles au cours desquels ma drépanocytose diminue ou empire | ||
| Emotional representation | 33 | I get depressed when I think about my sickle cell disease | Je déprime quand je pense à ma drépanocytose | |
| 34 | When I think about my sickle cell disease I get upset | Quand j’y pense, ma drépanocytose m’inquiète | ||
| 35 | My sickle cell disease male me feel angry | Ma drépanocytose me met en colère | ||
| 36 | R | My sickle cell disease does not worry me | Ma drépanocytose ne me gêne pas | |
| 37 | Having this sickle cell disease makes me feel anxious | À cause de la drépanocytose, je suis anxieux | ||
| 38 | My sickle cell disease makes me feel afraid | Ma drépanocytose me fait peur | ||
| Psychological attribution | 44 | Stress or worry | C’est le stress ou l’ennui | |
| 45 | Family problems or worries caused my illness | C’est des problèmes de familles | ||
| 55 | My mental attitude | C’est mon attitude mentale | ||
| 61 | Overwork | C’est lié à ma surcharge de travail | ||
| 68 | My emotional state | C’est dû à mon état émotionnel | ||
| 70 | My personality | C’est ma personnalité | ||
| Risk factor – Hereditary | 39 | N | It runs in my family | C’est courant dans ma famille |
| 40 | N | It is a disease of the origins | C’est une maladie des origines | |
| 51 | N | It is hereditary or a genetic disease | C’est héréditaire ou génétique | |
| 57 | N | It is passed from parents to children | C’est transmis des parents aux enfants | |
| Risk factor – Blood | 41 | N | It is a lack of blood | C’est un manque de globule |
| 47 | N | It is a disease of the blood | C’est une maladie du sang | |
| 53 | N | It is a poor circulation of blood | C’est une mauvaise circulation du sang | |
| 59 | N | It is due to incompatible bloods | C’est dû à des sangs incompatibles | |
| 64 | It is a poor quality of blood | C’est la mauvaise qualité du sang | ||
| Risk factor – other | 43 | Diet or eating habits | C’est lié aux habitudes alimentaires | |
| 46 | N | It is a disease from Africa | C’est une maladie de l’Afrique | |
| 49 | My own behaviour | C’est dû à mon propre comportement | ||
| 53 | Poor medical care in my past | C’est dû à de mauvais soins médicaux dans mon passé personnel | ||
| 62 | Ageing | C’est dû au vieillissement | ||
| 63 | N | It is the poor sperm quality | C’est le mauvais sperme | |
| 65 | Alcohol | C’est dû à ma consommation d’alcool | ||
| 66 | Smoking | C’est dû à ma consommation de tabac | ||
| Immunity | 50 | A germ or virus | C’est dû à un microbe ou un virus | |
| 52 | Pollution in the environment | C’est dû à la pollution de l’environnement | ||
| 58 | N | It is the heat | C’est la chaleur | |
| 67 | Altered immunity | C’est la détérioration de l’immunité | ||
| Accident or chance | 42 | Chance or bad luck | C’est le hasard ou la malchance | |
| 48 | N | It is a divine punishment | C’est une punition divine | |
| 54 | N | It is a malediction | C’est une malédiction | |
| 60 | N | It is due to spirits or spells | C’est dû à des esprits ou à des sorts | |
| 69 | Accident or injury | C’est dû à un accident ou une blessure |
Note: R, reverse item; N, new item.
Fit indices presentation (Hooper et al., 2008).
| Indices | Presentation | Cut off | Reference |
|---|---|---|---|
| SRMR | Absolute fit indice which determine how well an | <0.08 | Hu & Bentler, |
| RMSEA | The RMSEA tells us how well the model, with unknown but optimally chosen parameter estimates would fit the populations covariance matrix. the RMSEA favours parsimony in that it will choose the model with the lesser number of parameters. | <0.07 | Steiger, |
| relative/normed chi square | The Chi-Square value is the traditional measure for evaluating overall model fit and, assesses the magnitude of discrepancy between the sample and fitted covariances matrices. Because the Chi-Square statistic is in essence a statistical significance test it is sensitive to sample size which means that the Chi-Square statistic nearly always rejects the model when large samples are used. One example of a statistic that minimises the impact of sample size on the Model Chi-Square is Wheaton | [2;5] | Wheaton et al., |
| CFI | The Comparative Fit Index is a revised form of the NFI which takes into account sample size that performs well even when sample size is small. | >0.90 | Hu & Bentler, |
| NNFI/TLI | the Non-Normed Fit Index assesses the model by comparing the χ2 value of the model to the χ2 of the null model. | >0.90 | Hooper et al., |
Goodness-of-fit indices for the original and revised models of the SCD-IPQ-R (n = 406).
| Cut-off | SRMR | RMSEA | CFI | TLI | χ²/dF | AIC | |||
|---|---|---|---|---|---|---|---|---|---|
| <.08 | <.07 | 90% CI | > .90 | > .90 | dF | <5 | Lowest | ||
| Model 1 | .077 | .058 | .054-.061 | 0.83 | 0.81 | 1516 | 644 | 2.35 | 42934 |
| Model 2 | .075 | .058 | .054-.062 | 0.84 | 0.83 | 1353 | 573 | 2.36 | 40629 |
| Model 3 | .071 | .048 | .044-.052 | .089 | .088 | 1100 | 565 | 1.95 | 40392 |
| Model 4 | .058 | .042 | .038-.047 | .092 | .091 | 973.5 | 562 | 1.73 | 40272 |